A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

The US Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors.

Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

In the space of a month, I went from working full time as a lecturer, having an active social life, exercising and trying my ...

Results of study directed by Rodrigo Toledo, Head of the Vall d'Hebron Institute of Oncology's (VHIO) Biomarkers and Clonal ...

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Laryngeal cancer affects the larynx (voice box) and often can be curable. Here are the treatment and surgical options and how ...